Genetic diseases of muscle

Neurologic Clinics

Volumn 20, Issue 3, 2002, Pages 645-678

  Wagner, Kathryn R ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; DYSTROBREVIN; SARCOGLYCAN; SYNTROPHIN;

BASEMENT MEMBRANE; CELL NUCLEUS; CHROMOSOMAL LOCALIZATION; CHROMOSOME MUTATION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; MUSCULAR DYSTROPHY; MYOPATHY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SARCOLEMMA; SARCOMERE;

GENETIC MARKERS; GENETIC SCREENING; GENOTYPE; HUMANS; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DISEASES; MUSCULAR DYSTROPHIES;

EID: 0036699086     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(02)00002-6     Document Type: Review

References (158)

1. Monaco AP, Neve RL, Colletti-Feener C, et al. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986;323:646-50.
2. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-17.
3. Hoffman EP, Brown Jr. RH, Kunkel LM. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-28.
4. Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998;20:31-6.
5. Illarioshkin SN, Ivanova-Smolenskaya IA, Greenberg CR, et al. Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. Neurology 2000;55:1931-3.
6. Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994;8:323-7.
7. Muchir A, Bonne G, Van Der Kooi AJ, et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb-girdle muscular dystrophy with atrioventricular conduction disturbances (LGMDIB). Hum Mol Genet 2000;9:1453-9.
8. Tsujino S, Nonaka I, DiMauro S. Glycogen storage myopathies. Neurol Clin 2000;18:125-50.
9. Vladutiu G. The molecular diagnosis of metabolic myopathies. Neurol Clin 2000;18:53-104.
10. Pourmand R. Metabolic Myopathies. Neurol Clin 2000;18:1-14.
11. Griggs RC, Moxley 3rd RT, Mendell JR, et al. Prednisone in Duchenne dystrophy: A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991;48:383-8.
12. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-7.
13. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974;2:1409-12.
14. Hoffman EP, Arahata K, Minetti C, et al. Dystrophinopathy in isolated cases of myopathy in females. Neurology 1992;42:967-75.
15. Nigro V. Prospective study of X-linked progressive muscular dystrophy in Campania. Muscle Nerve 1983;6:253-62.
16. Finsterer J, Stollberger C. Cardiac involvement in primary myopathies. Cardiology 2000;94:1-11.
17. Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol 1997;12:329-343.
18. Bardoni A, Sironi M, Felisari G, et al. Absence of brain Dpl40 isoform and cognitive impairment in Becker muscular dystrophy. Lancet 1999;353:897-8.
19. Bresolin N, Castelli E, Comi GP, et al. Cognitive impairment in Duchenne muscular dystrophy. Neuromuscul Disord 1994;4:359-69.
20. Barbujani G, Russo A, Danieli GA, et al. Segregation analysis of 1885 DMD families: significant departure from the expected proportion of sporadic cases. Hum Genet 1990;84:522-6.
21. Miller RG, Hoffman EP. Molecular diagnosis and modern management of Duchenne muscular dystrophy. Neurol Clin 1994;12:699-725.
22. Beggs AH, Koenig M, Bocye FM, et al. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 1990;86:45-8.
23. Mendell JR, Buzin CH, Feng J, et al. Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology 2001;57:574-5.
24. Prior TW, Bartolo C, Pearl DK, et al. Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet 1995;57:22-3.
25. Barton-Davis ER, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104:375-81.
26. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001;49:706-11.
27. Serrano C, Wall C, Moore S, et al. Gentamicin treatment for muscular dystrophy patients with stop codon mutations. Neurology 2001;56(Suppl 3):A79.
28. Bushby KMD. The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms. Hum Mol Genet 1999;8:1875-82.
29. Speer MC, Gilchrist JM, Stajich JM, et al. Evidence for anticipation in autosomal dominant limb-girdle muscular dystrophy. J Med Genet 1998;35:305-8.
30. Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000;9:2141-7.
31. Salmikangas P, Mykkanen OM, Gronholm M, et al. Myotilin, a novel sarcomeric protein with two Ig-like domains, is encoded by a candidate gene for limb-girdle muscular dystrophy. Hum Mol Genet 1999;8:1329-36.
32. Speer MC, Yamaoka LH, Gilchrist JM, et al. Confirmation of genetic heterogeneity in limb-girdle muscular dystrophy: linkage of an autosomal dominant form to chromosome 5q. Am J Hum Genet 1992;50:1211-7.
33. Van Der Kooi AJ, Van Meegen M, Ledderhof TM, et al. Genetic localization of a newly recognized autosomal dominant limb-girdle muscular dystrophy with cardiac involvement (LGMD1B) to chromosome 1q11-21. Am J Hum Genet 1997;60:891-5.
34. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998;18:365-8.
35. McNally EM, De Sa Moreira E, Duggan DJ, et al. Caveolin-3 in muscular dystrophy. Hum Mol Genet 1998;7:871-7.
36. Sunada Y, Ohi H, Hase A, et al. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum Mol Genet 2001;10:173-8.
37. Betz RC, Schoser BG, Kasper D, et al. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 2001;28:218-9.
38. McNally EM, Ly CT, Kunkel LM. Human epsilon-sarcoglycan is highly related to alpha-sarcoglycan (adhalin), the limb-girdle muscular dystrophy 2D gene. FEBS Lett 1998;422:27-32.
39. Angelini C, Fanin M, Freda MP, et al. The clinical spectrum of sarcoglycanopathies. Neurology 1999;52:176-9.
40. Allamand V, Donahue KM, Straub V, et al. Early adenovirus-mediated gene transfer effectively prevents muscular dystrophy in alpha-sarcoglycan-deficient mice. Gene Ther 2000;7:1385-91.
41. Stedman H, Wilson JM, Finke R, et al. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Ther 2000;11:777-90.
42. Beckmann JS, Richard I, Hillaire D, et al. A gene for limb-girdle muscular dystrophy maps to chromosome 15 by linkage. C R Acad Sci III 1991;312:141-8.
43. Pollitt C, Anderson LVB, Pogue R, et al. The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach. Neuromuscul Disord 2001;11:287-96.
44. Chou FL, Angelini C, Daentl D, et al. Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population. Neurology 1999;52:1015-20.
45. Richard I, Roudaut C, Saenz A, et al. Calpainopathy - A survey of mutations and polymorphisms. Am J Hum Genet 1999;64:1524-40.
46. Tidball JG, Spencer MJ. Molecules in focus Calpains and muscular dystrophies. Int J Biochem Cell Biol 2000;32:1-5.
47. Bushby KMD. Making sense of the limb-girdle muscular dystrophies. Brain 1999;122:1403-20.
48. Bashir R, Britton S, Strachan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998;20:37-42.
49. Bashir R, Strachan T, Keers S, et al. A gene for autosomal recessive limb-girdle muscular dystrophy maps to chromosome 2p. Hum Mol Genet 1994;3:455-7.
50. Matsuda C, Hayashi YK, Ogawa M, et al. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet 2001;10:1761-6.
51. Ho M, Gallardo E, McKenna-Yasek D, et al. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and miyoshi myopathy. Ann Neurol 2002;51:129-32.
52. McNally EM, Passos-Bueno MR, Bonnemann CG, et al. Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am J Hum Genet 1996;59:1040-7.
53. Calvo F, Teijeira S, Fernandez JM, et al. Evaluation of heart involvement in γ-sarcoglycanopathy (LGMD2C). A study of ten patients. Neuromuscul Disord 2000;10:560-6.
54. Nogauchi S, McNally EM, Ben Othmane K, et al. Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 1995;270:819-22.
55. Pogue R, Anderson LVB, Pyle A, et al. Strategy for mutation analysis in the autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 2001;11:80-7.
56. Van Der Kooi AJ, De Voogt WG, Barth PG, et al. The heart in limb-girdle muscular dystrophy. Heart 1998;79:73-7.
57. Roberds SL, Letureq F, Allamand V, et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 78, 1994.
58. Carrie A, Piccolo F, Letureq F, et al. Mutational diversity and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D). J Med Genet 1997;34:470-5.
59. Duclos F, Broux O, Bourg N, et al. Beta-sarcoglycan: genomic analysis and identification of a novel missense mutation in the LGMD2E Amish isolate. Neuromuscul Disord 1998;8:30-8.
60. Nigro V, De Sa Moreira E, Piluso G, et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F is caused by a mutation in the δ;-sarcoglycan gene. Nat Genet 1996;14:195-8.
61. Nigro V, Okazaki Y, Belsito A, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997;6:601-7.
62. Sakamoto A, Ono K, Abe M, et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997;94:1373-8.
63. Moreira ES, Wiltshire TJ, Faulkner G, et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet 2000;24:163-6.
64. Valle G, Faulkner G, De Antoni A, et al. Telethonin, a novel sarcomeric protein of heart and skeletal muscle. FEBS Lett 1997;415:163-8.
65. Weiler T, Greenberg CR, Zeleinski T, et al. A gene for autosomal recessive limb-girdle muscular dystrophy in Manitoba Hutterites maps to chromosome region 9q31-q33: evidence for another limb-girdle muscular dystrophy locus. Am J Hum Genet 1998;63:140-7.
66. Frosk P, Weiler T, Nylen E, et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet 2002;70:663-72.
67. Driss A, Amouri R, Ben Hamida C, et al. A new locus for autosomal recessive limb-girdle muscular dystrophy in a large consanguineous Tunisian family maps to chromosome 19q13.3. Neuromuscul Disord 2000;10:240-6.
68. Brockington M, Blake DJ, Prandini P, et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycoslyation of alpha-dystroglycan. Am J Hum Genet 2001;69:1198-209.
69. Brouwer OF, Padberg GW, Ruys CJ, et al. Hearing loss in facioscapulohumeral muscular dystrophy. Neurology 1991;41:1878-81.
70. Padberg GW, Brouwer OF, De Keizer RJW, et al. Retinal vascular disease and sensorineural deafness are part of facioscapulohumeral muscular dystrophy. Am J Hum Genet 1992;51:A104.
71. Wijmenga C, Padberg GW, Moerer P, et al. Mapping of facioscapulohumeral muscular dystrophy gene to chromosome 4q35-qter by multipoint linkage analysis and in situ hybridization. Genomics 1991;9:570-5.
72. Van Deutekom JC, Bakker E, Lemmers RJ, et al. Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26: implications for genetic counselling and etiology of FSHD1. Hum Mol Genet 1996;5:1997-2003.
73. Wijmenga C, Sandkuijl LA, Moerer P, et al. Genetic linkage map of facioscapulohumeral muscular dystrophy and five polymorphic loci on chromosome 4q35-qter. Am J Hum Genet 1992;51:411-5.
74. Tawil R, Forrester J, Griggs RC, et al. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY group. Ann Neurol 1996;39:744-8.
75. Flanigan KM, Coffeen CM, Sexton L, et al. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord 2001;11:525-9.
76. Upadhyaya M, Maynard J, Rogers MT, et al. Improved molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD): validation of the differential double digestion for FSHD. J Med Genet 1997;34:476-9.
77. Tawil R, Figlewicz DA, Griggs RC, et al. Facioscapulohumeral dystrophy: a distinct regional myopathy with a novel molecular pathogenesis. FSH Consortium. Ann Neurol 1998;43:279-82.
78. Emery AE. Emery-Dreifuss muscular dystrophy - a 40 year retrospective. Neuromuscul Disord 2000;10:228-32.
79. Manilal S, Nguyen TM, Sewry CA, et al. The Emery-Dreifuss muscular dystrophy protein, emerin, is a nuclear membrane protein. Hum Mol Genet 1996;5:801-8.
80. Nagano A, Koga R, Ogawa M, et al. Emerin deficiency at the nuclear membrane in patients with Emery-Dreifuss muscular dystrophy. Nat Genet 1996;12:254-9.
81. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999;21:285-8.
82. Hill ME, Creed GA, McMullan TFW, et al. Oculopharyngeal muscular dystrophy: Phenotypic and genotypic studies in a UK population. Brain 2001;124:522-6.
83. Tome FM, Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol 1980;49:85-7.
84. Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998;18:164-7.
85. Lieberman AP, Fischbeck KH. Triplet repeat expansion in neuromuscular disease. Muscle Nerve 2000;23:843-50.
86. Calado A, Tome FM, Brais B, et al. Nuclear inclustions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 2000;9:2321-8.
87. Moxley RT, Meda G. Myotonic Dystrophy. In: Neuromuscular Diseases: From Basic Mechanisms to Clinical Management. Deymeer F (ed). Monogr Clin Neurosci. Basal, Karger, 2000, vol. 18, pp. 61-78.
88. Roig M, Balliu PR, Navarro C, et al. Presentation, clinical course, and outcome of the congenital form of myotonic dystrophy. Pediatr Neurol 1994;11:208-13.
89. Turnpenny P, Clark C, Kelly K. Intelligence quotient profile in myotonic dystrophy, intergenerational deficit, and correlation with CTG amplification. J Med Genet 1994;31:300-5.
90. Kimura J. Electrodiagnosis in diseases of nerve and muscle: Principles and practice (ed 2). Philadelphia: F. A. Davis Company, 1989.
91. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808.
92. Fu YH, Pizzuti A, Fenwick Jr. RG, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255:1256-8.
93. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 1992;255:1253-8.
94. Carango P, Noble JE, Marks HG, et al. Absence of myotonic dystrophy protein kinase (DMPK) mRNA as a result of a triplet repeat expansion in myotonic dystrophy. Genomics 1993;18:340-8.
95. Larkin K, Fardaei M. Myotonic dystrophy - a multigene disorder. Brain Res Bull 2001;56:389-95.
96. Consortium TIMD. New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). Neurology 2000;54:1218-21.
97. Harper PS. Myotonic dystrophy as a trinucleotide repeat disorder - A clinical perspective. In: Wells RD, Warren ST (eds). Genetic Instabilities and Hereditary Neurological Diseases. San Diego, Academic Press, 1998, pp. 115-130.
98. Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994;44:1448-52.
99. Meola G, Sansone V, Rotondo G, et al. PROMM in Italy: clinical and biomolecular findings. Acta Myol. 1998;2:21-6.
100. Udd B, Krahe R, Wallgren-Pettersson C, et al. Proximal myotonic dystrophy - a family with autosomal dominant muscular dypstrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromusc Disord 1997;7:217-28.
101. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-7.
102. Day JW, Roelofs R, Leroy B, et al. Clinical and genetic characteristics of a five-generation family with a novel form of myotonic dystrophy (DM2). Neuromusc Disord 1999;9:19-27.
103. Schneider C, Ziegler A, Ricker K, et al. Proximal myotonic myopathy: Evidence for anticipation in families with linkage to chromosome 3q. Neurology 55, 2000.
104. Brockington M, Yuva Y, Prandini P, et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001;10:2851-9.
105. Jones KJ, Morgan G, Johnston H, et al. The expanding phenotype of laminin α2 chain (merosin) abnormalities: case series and review. J Med Genet 2001;38:649-57.
106. Tome FM, Evangelista T, Leclerc A, et al. Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III 1994;317:351-7.
107. Helbling-Leclerc A, Zhang X, Topaloglu H, et al. Mutations in the laminin α2-chain gene (LAMA2) cause merosin-deficient congential muscular dystrophy. Nat Genet 1995;11:216-8.
108. Shorer Z, Philpot J, Muntoni F, et al. Demyelinating peripheral neuropathy in merosin-deficient congenital muscular dystrophy. J Child Neurol 1995;10:472-5.
109. Moll J, Barzaghi P, Lin S, et al. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 2001;413:302-7.
110. Toda T, Kobayashi K, Kondo-Iida E, et al. The Fukuyama congenital muscular dystrophy story. Neuromusc Disord 2000;10:153-9.
111. Fukuyama Y, Osawa M, Suzuki H. Congenital muscular dystrophy of the Fukuyama type-clinical, genetic and pathological considerations. Brain Dev 1981;3:1-29.
112. Kobayashi K, Nakahori Y, Miyake M, et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998;394:388-92.
113. Hayashi YK, Ogawa M, Tagawa K, et al. Selective deficiency of α-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 2001;57:115-21.
114. Cormand B, Pihko H, Bayes M, et al. Clinical and genetic distinction between Walker-Warburg syndrome and muscle-eye-brain disease. Neurology 2001;56:1059-69.
115. Yoshida A, Kobayashi K, Manya H, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001;1:717-24.
116. Jobsis GJ, Boers JM, Barth PG, et al. Bethlem myopathy: a slowly progressive congenital muscular dystrophy with contractures. Brain 1999;122:649-55.
117. Lamande SR, Morgelins M, Selan C, et al. Kinked collagen VI tetramers and reduced microfibril formation as a result of Bethlem myopathy and introduced triple helical glycine mutations. J Biol Chem 2001; In press.
118. Scacheri PC, Gillanders EM, Subramony SH, et al. Novel mutations in collagen VI genes: expansion of the Bethlem myopathy phenotype. Neurology 2002;58:593-602.
119. Vanegas OC, Bertini E, Zhang R-Z, et al. Ullrich sleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci USA 2001;98:7516-21.
120. Flanigan KM, Kerr L, Bromberg MB, et al. Congenital muscular dystrophy with rigid spine syndrome: a clinical, pathological, radiological and genetic study. Ann Neurol 2000;47:152-61.
121. Moghadaszadeh B, Petit N, Jaillard C, et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat Genet 2001;29:17-8.
122. Hayashi K, Miller RG, Brownell AK. Central core diseases: ultrastructure of the sarcoplasmic reticulum and T-tubules. Muscle Nerve 1989;12:95-102.
123. Quane KA, Healy JM, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993;5:51-5.
124. Zhang Y, Chen HS, Khanna VK, et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993;5:46-50.
125. Loke J, MacLennan DH. Malignant hyperthermia and central core disease: disorders of Ca2+ release channels. Am J Med 1998;104:470-86.
126. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000;15:410-7.
127. Spiro AJ, Shy GM, Gonatas NK. Myotubular myopathy. Persistence of fetal muscle in an adolescent boy. Arch Neurol 1966;14:1-14.
128. Laporte J, Hu LJ, Kretz C, et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 1996;13:175-82.
129. Taylor GS, Maehama T, Dixon JE. Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. Proc Nat Acad Sci 2000;97:8910-5.
130. Karpati G, Carpenter S, Nelson RF. Type I muscle fibre atrophy and central nuclei: A rare familial neuromuscular disease. J Neurol Sci 1970;10:489.
131. Kerst B, Mennerich D, Schuelke M, et al. Heterozygous myogenic factor 6 mutation associated with myopathy and severe course of Becker muscular dystrophy. Neuromuscul Disord 2000;10:572-7.
132. Wallergren-Pettersson C, Clarke A, Samson F, et al. The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. J Med Genet 1995;32:673-9.
133. Sanoudou D, Beggs AH. Clinical and genetic heterogeneity in nemaline myopathy-a disease of skeletal muscle thin filaments. Trends Mol Med 2001;7:362-8.
134. Ryan MM, Schnell C, Strickland CD, et al. Nemaline myopathy: a clinical study of 143 cases. Ann Neurol 2001;50:312-20.
135. Wallgren-Pettersson C, Laing NG. Report of the 70th ENMC International Workshop: nemaline myopathy, 11-13 June 1999, Naarden. The Netherlands. Neuromuscul Disord 2000;10:299-306.
136. Laing NG, Wilton SD, Akkari PA, et al. A mutation in the alpha-tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy NEM1. Nat Genet 1995;9:75-9.
137. Pelin K, Hilpela P, Donner K, et al. Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. Proc Natl Acad Sci USA 1999;96:2305-10.
138. Nowak KJ, Wattanasirichaigoon D, Goebel HH, et al. Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet 1999;23:208-12.
139. Donner K, Ollikainen M, Pelin K, et al. Mutations in the β-Tropomyosin (TPM2) gene in rare cases of autosomal dominant nemaline myopathy. Neuromusc Disord 2000;10:342-3.
140. Johnston JJ, Kelley RI, Crawford TO, et al. A novel nemaline myopathy in the Amish caused by a mutation in troponin TI. Am J Hum Genet 2000;67:814-21.
141. Welander L. Myopathia distalis tarda hereditaria. Acta Med Scand 1951;141:1-24.
142. Barohn RJ, Amato AA, Griggs RC. Overview of distal myopathies: from the clinical to the molecular. Neuromuscul Disord 1998;8:309-16.
143. Ahlberg G, von Tell D, Borg K, et al. Genetic linkage of Welander distal myopathyto chromosome 2p 13. Ann Neurol 1999;46:399-404.
144. Haravuori H, Mskels-Bengs P, Figlewicz DA, et al. Tibial muscular dystrophy and late-onset distal myopathy are linked to the same locus on chromosome 2q. Neurology 1998;50:A186.
145. Garvey SM, Chandrika R, Lerner AP, et al. The muscular dystrophy with myositis (mdm) mouse mutation disrupts a skeletal muscle-specific domain of titin. Genomic 2002;79:146-9.
146. Haravuori H, Vihoa A, Straub V, et al. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: Titin is the candidate gene. Neurology 2001;56:869-77.
147. Markesbery WR, Griggs RC, Leach RP, et al. Late onset hereditary distal myopathy. Neurology 1974;24:127-34.
148. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001;29:83-7.
149. Kayashima T, Matsuo H, Satoh A, et al. Nonaka myopathy is caused by mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE). J Hum Genet 2002;47:77-9.
150. Nonaka I. Distal myopathies. Curr Opin Neurol 1999;12:493-9.
151. Sunohara N, Nonaka I, Kamei N, et al. Distal myopathy with rimmed vacuole formation. A follow-up study. Brain 1989;112:65-83.
152. Voit T, Kutz P, Leube B, et al. Autosomal dominant distal myopathy: further evidence of a chromosome 14 locus. Neuromusc Disord 2001;11-9.
153. Nakano S, Engel AG, Waclwik AJ, et al. Myofibrillary myopathy with abnormal foci of desmin positivity. I. Light and electron microscopy analysis of 10 cases. J Neuropathol Exp Pathol 1996;55:549-62.
154. Fardeau M, Godet-Guillain J, Tome FM, et al. [A new familial muscular disorder demonstrated by the intra-sarcoplasmic accumulation of a granulo-filamentous material which is dense on electron microscopy]. Rev Neurol (Paris) 1978;134:411-25.
155. Carlsson L, Thornell LE. Desmin-related myopathies in mice and man. Acta Physiol Scand 2001;171:341-8.
156. Vicart P, Caron A, Guicheney P, et al. A missense mutation in the αβ-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 1998;20:92-5.
157. Goldfarb LG, Park KY, Cervenakova L, et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 1998;19:402-3.
158. Dalakas MC, Park KY, Semino-Mora C, et al. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000;342:770-80.